Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
470.3 USD | -0.74% |
|
-0.75% | +15.58% |
07-02 | FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis | MT |
07-02 | Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.58% | 122B | |
+16.60% | 113B | |
+17.55% | 26.22B | |
-24.33% | 19.01B | |
-19.14% | 15.71B | |
-17.95% | 15.22B | |
-46.81% | 14.72B | |
+58.78% | 14.58B | |
+4.91% | 13.84B | |
+100.06% | 10.4B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Transcript : Vertex Pharmaceuticals Incorporated Presents at 31st Annual JPMorgan Healthcare Conference, Jan-07-2013 10